Clinical Nutrition

ENTEREX® HEPATIC

  • Contains Arginine for Improved Ammonia Metabolism
  • No Phenylalanine and Low in Methionine, to Reduce Risk of Hepatic Damage and Encephalopathy
  • A High Ratio of Branch-Chain Amino Acids (BCAA) to Aromatic Amino Acids (AAA)
  • Medium-Chain (MCT) and Long-Chain (LCT) Triglycerides for Improved Fat Digestion and Absorption

Available Options

* Sale unit:
Qty:   $365.00  
ENTEREX® HEPATIC

Specialized Nutritional Formula for People with Liver Disease

 

Enterex® Hepatic is specially formulated to help promote positive nitrogen balance and improve the nutritional status of individuals with liver disease while minimizing the risk of hepatic encephalopathy.

  • A high ratio of Branched-Chain Amino Acids (BCAA) to Aromatic Amino Acids (AAA). (32:1 molar ratio)
  • Medium-Chain (MCT) and Long-Chain (LCT) Triglycerides for improved fat digestion and absorption
  • No phenylalanine and low in methionine, to reduce risk of hepatic damage and encephalopathy
  • Contains arginine for improved ammonia metabolism
  • No added sugar or simple carbohydrates, for improved glycemic control

Low in electrolytes for management of edema

 

PRESENTATION: POWDER

Catalog Number Units per Case Size
91111 24 pouches 110 g

 

NUTRITIONAL INFORMATION
Nutrients per serving (110 g)


Calories (kcal) 500
Energy (kJ) 2092
Protein (g)
(as amino acids)
18.6

L-Leucine (g)

3.38

L-Isoleucine (g)

2.75

Glycine (g)

0.88

L-Lysine (g)
(as L-Lysine acetate)

1.63

L-Valine (g)

2.50

L-Proline (g)

1.75

L-Alanine (g)

1.62

L-Arginine (g)

1.62

L-Threonine (g)

0.75

L-Serine (g)

0.50

L-Histidine (g)

0.62

L-Methionine (g)

0.25

L-Tryptophan (g)

0.18

L-Cysteine (g)

0.06

L-Tyrosine (g)

0.08
Carbohydrate (g) 71.7
Fat (g) 15.4

Ingredients: Maltodextrin, MCT oil, canola oil, L-leucine, L-isoleucine, L-valine, L-lysine acetate, L-proline, L-alanine, L-arginine, glycine, L-threonine, L-histidine, citric acid, L-serine, carrageenan, L-methionine, lecithin, L-tryptophan, monoglycerides and diglycerides, taurine, sucralose, L-tyrosine, L-cysteine, carnitine, natural and artificial flavors.

Caloric Density (kcal/mL) 1.2
Caloric Distribution
Protein (% kcal) 14.9
Carbohydrate (% kcal) 57.4
Fat (% kcal) 27.7
Total Cal/g N 168.:1
Non-Protein Cal/g N 143:1
Gluten free Yes
Lactose free Yes

Flavor: Vanilla

 

 

DIRECTIONS OF USE

Preparation and Serving Instructions:

Avoid contamination during preparation and use.

  1. Pour 350 mL (11.6 fl oz) of water into a blender. If a blender is not available, refer to Package Insert.
  2. Add one package of Enterex® Hepatic.
  3. Blend at low speed for approximately 30 seconds.

Serve immediately, or refrigerate.

 

 

PRECAUTIONS

For oral or tube feeding only.
Not for intravenous administration.
No data has been reported for the use of Enterex®a Hepatic in children or pregnant or lactating women.
Consult package instructions before use.
USE UNDER PROFESSIONAL SUPERVISION

FREQUENTLY ASKED QUESTIONS

 

We currently have no frequently asked questions for this product. If you have any questions please click here.

  • Johnson T, Overgard E, Cohen A E, DiBaise J K. Nutrition Assessment and Management in Advanced Liver Disease. Nutr Clin Pract 2013 28: 15
  • CHEUNG K, LEE S S, RAMAN M. Prevalence and Mechanisms of Malnutrition in Patients With Advanced Liver Disease, and Nutrition Management Strategies. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:117–125
  • Ishikawa T. Early administration of branched-chain amino acid granules. World J Gastroenterol 2012 September 7; 18(33): 4486-4490
  • Rivera R, Abilés J. Soporte nutricional en el paciente con cirrosis hepática. j.gastrohep.2012.03.001
  • Garcia J J, Rodero C, Calañas-Continente A. Importancia de la nutrición en enfermos con encefalopatía hepática. Nutr Hosp. 2012;27(2):372-381
  • Delich P C, Siepler J K, Parker P. Liver disease. En Gottschich M M (Ed). The A.S.P.E.N. Nutrition Support Core Curriculum: A case-based approach - The adult patient. USA Aspen Publishers, Inc; 2007. Capítulo 28: 540-577.
  • Plauth M, Cabre E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, Ferenci P, Holm E, Vom Dahl S, Muller MJ, Nolte W. -ESPEN - Guidelines on Enteral Nutrition: Liver Disease. Clinical Nutrition (2006) 25, 285–294.
  • Muto Y, Sato S, Watanabe A, for the Lotus Group, et al. Effects of oral branched chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005, 3:705-13.
  • Marchesini G, Bianchi G, Merli M, The Italian BCAA Study Group, et al. Branchedchain Nutritional supplementation with amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003, 124:1792-801.
  • Patton K, Aranda-Michel J. Nutritional aspects in liver disease and liver transplantation. NCP 2002; 17: 332-340.
  • Teran C, McCullough A. Nutrition in Liver Diseases. En Gottschlich M, Fuhrman M, Hammond K, Holcombe B, Seidner D (eds). The science and practice of nutrition support. A case-based core curriculum. USA Aspen Publishers, Inc; 2001. Capitulo 26: 537 – 552.
  • Mendenhall CL, Moritz TE, Roselle GA, et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group # 275. J Parenter Enteral Nutr 1995, 19:258-65.
  • Chin SE, Shepherd RW, Thomas BJ, et al. Nutritional support in children with end-stage liver disease: a randomized crossover trial of a branched-chain amino acid supplement. Am J Clin Nutr 1992, 56:158-63.
  • Yoshida T, Muto Y, Moriwaki H, Yamato M. Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis. Gastroenterol Japan 1989; 24:692-8.
  • Mendenhall CL, Tosch T, Weesner RE, et al. VA cooperative study on alcoholic hepatitis. II: prognostic significance of protein-calorie malnutrition. Am J Clin Nutr 1986; 43:213-8